Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) has shared an update.
Zai Lab Limited has filed preliminary proxy materials with the U.S. Securities and Exchange Commission for its 2026 annual general meeting of shareholders. The documents, which also serve as a circular for Hong Kong shareholders, outline proposals including director re-elections and the appointment of independent auditors for the year ending December 31, 2026.
Shareholders will also be asked to approve, on an advisory basis, executive compensation and to grant the board general mandates to issue and repurchase up to 10% of the company’s ordinary shares and American Depositary Shares. The final proxy statement and meeting notice are expected to be published in English and Chinese on the Hong Kong stock exchange’s website around April 28, 2026, underscoring Zai Lab’s ongoing compliance with both U.S. and Hong Kong listing regimes.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong, focusing on the development and commercialization of innovative medicines. The company targets both global markets and Greater China investors through its dual U.S. and Hong Kong regulatory and listing presence, reflecting its cross-border capital markets strategy.
Average Trading Volume: 10,054,207
Technical Sentiment Signal: Sell
Current Market Cap: HK$19.73B
See more insights into 9688 stock on TipRanks’ Stock Analysis page.